Dr. Yuliya Linhares, M.D.
Claim this profileMiami Cancer Institute at Baptist Health, Inc.
Affiliated Hospitals
Miami Cancer Institute At Baptist Health, Inc.
Baptist Hospital Of Miami
Clinical Trials Yuliya Linhares, M.D. is currently running
Zanubrutinib + Pemetrexed
for CNS Lymphoma
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.
Recruiting
1 award
Phase 2
Tazemetostat + Lenalidomide + Rituximab
for Follicular Lymphoma
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Recruiting
1 award
Phase 3
4 criteria
More about Yuliya Linhares, M.D.
Clinical Trial Related
6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Yuliya Linhares, M.D. has experience with
- Rituximab
- Pemetrexed
- Zanubrutinib
- Loncastuximab Tesirine
- Brentuximab Vedotin
- Dacarbazine
Breakdown of trials Yuliya Linhares, M.D. has run
Central Nervous System Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yuliya Linhares, M.D. specialize in?
Yuliya Linhares, M.D. focuses on Cancer and Relapse. In particular, much of their work with Cancer has involved treating patients, or patients who are undergoing treatment.
Is Yuliya Linhares, M.D. currently recruiting for clinical trials?
Yes, Yuliya Linhares, M.D. is currently recruiting for 2 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Yuliya Linhares, M.D. has studied deeply?
Yes, Yuliya Linhares, M.D. has studied treatments such as Rituximab, Pemetrexed, Zanubrutinib.
What is the best way to schedule an appointment with Yuliya Linhares, M.D.?
Apply for one of the trials that Yuliya Linhares, M.D. is conducting.
What is the office address of Yuliya Linhares, M.D.?
The office of Yuliya Linhares, M.D. is located at: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida 33176 United States. This is the address for their practice at the Miami Cancer Institute at Baptist Health, Inc..
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.